Journals / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 3

Aplastic Anemia Frequency and Management in Pediatric Liver Transplantations Due to Non-A-E Hepatitis

Pages
313–317
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The clinicians should be alert after orthotropic liver transplantation patient could develop aplastic anemia and early treatment with immunosuppressive therapies result in a more successful outcome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Hepatitis-associated aplastic anemia (HAAA) is a rare complication that presented with bone marrow failure after acute hepatitis.
📊
Key Findings & Data:HAAA usually occurs in adolescent men within 1-6 months following hepatitis.
💡
Conclusion & Impact:The clinicians should be alert after orthotropic liver transplantation patient could develop aplastic anemia and early treatment with immunosuppressive therapies result in a more successful outcome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: Hepatitis-associated aplastic anemia (HAAA) is a rare complication that presented with bone marrow failure after acute hepatitis. HAAA usually occurs in adolescent men within 1-6 months following hepatitis. Most of HAAA’s etiology has non-A-E viral hepatitis. Methods: Our retrospective study included patients with acute fulminant hepatitis who had been treated in Ege University Pediatric Gastroenterology, Hepatology and Nutrition Department and İzmir Kent Hospital Clinical, laboratory, and epidemiological data of the patients were collected from the files. Results: In this study, 499 children underwent liver transplantation (LT) in two pediatric transplantation centers. Sixty-eight (13.6%) out of 499 patients, underwent liver transplantation due to fulminant hepatic failure (FHF). Therefore, a total of 64 patients (34 girls, 30 boys) with a diagnosis of FHF have included in the study. Thirty-two (50.0%) of 64 FHF were due to non-A-E hepatitis and 4 out of the 64 patients (6.2%) with FHF developed HAAA. All of the patients received prednisolone as immunosuppression treatment after LT. Three patients were also given Tacrolimus and 1 received an additional mycophenolate mofetil. One of the patients was given prednisolone and cyclosporine treatment without tacrolimus. Bone marrow transplantation was performed in 1 patient (25.0%). Two of the patients received immunosuppressive treatment including rabbit-derived anti-thymocyte globulin, cyclosporine, and initially prednisolone. Conclusion: In children who underwent liver transplantation for non-A-E FHF are at high risk to develop aplastic anemia. The clinicians should be alert after orthotropic liver transplantation patient could develop aplastic anemia and early treatment with immunosuppressive therapies result in a more successful outcome.

🔖

Cite This Article

TAŞCI, E. K., KARAKOYUN, M., KARADAŞ, N., ÖZDEMİR, H., KARAPINAR, D., KARACA, A. C., EROL, F., AYDOĞDU, S. (2021). Aplastic Anemia Frequency and Management in Pediatric Liver Transplantations Due to Non-A-E Hepatitis. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 3, 313–317. https://ajindex.com/articles/408653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Qureshi K, Sarwar U, Khallafi H. Severe aplastic anemia following acute hepatitis from toxic liver ınjury: literature review and case report of a successful outcome. Case Rep Hepatol. 2014
  2. 216570. [CrossRef] 2. Wang H, Tu M, Fu R, et al. The clinical and immune characteristics of patients with hepatitis-associated aplastic anemia in China. PLoS ONE. 2014
  3. 9(5):e98142. [CrossRef] 3. Sato S, Fuchinoue S, Abe M, et al. Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Clin Transplant. 1999
  4. 13(1 Pt 1):68-71. [CrossRef] 4. Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, MorenoOtero R. Systematic review: hepatitis-associated aplastic anaemia— a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009
  5. 30(5):436-443. [CrossRef] 5. Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011
  6. [CrossRef] 6. Itterbeek P, Vandenberghe P, Nevens F, et al. Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. Transpl Int. 2002
  7. 15(2- 3):117-123. [CrossRef] 7. Sanchez R, Rosenthal P, Goldsby R. Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children. Pediatr Blood Cancer. 2007
  8. 49(1):93-98. [CrossRef] 8. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006
  9. 108(8):2509-2519. [CrossRef] 9. Cudillo L. Aplastica anemia and viral hepatitis. Medit J Hemat Infect Dis. 2009
  10. 1(3):e2009026. [CrossRef] 10. Shouval DS, Mor E, Avitzur Y, et al. Living-related donor liver transplantation for children with fulminant hepatic failure in Israel. JPGN. 2009
  11. 48(4):451-455. [CrossRef] 11. Cattral MS, Langnas AN, Markin RS, et al. Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology. 1994
  12. Mali WP, Tan PL, Aw M, et al. Mismatched bone marrow transplantation for severe aplastic anaemia after liver transplantation for associated acute liver failure. Ann Acad Med Singapore. 2011
  13. Perkins JL, Neglia JP, Ramsay NKC, Davies SM. Successful bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation: long-term follow-up and outcome. Bone Marrow Transplant. 2001
  14. 28(5):523-526. [CrossRef] 14. Tzakis AG, Arditi M, Whitington PF, et al. Aplastic anemia c